---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-055288"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:23:49.358261+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharm amends ophthalmology license deal to allow incremental milestone payments

## Summary
- ABVC and BIOFIRST amended licensing agreement with ForSeeCon Eye Corp (FEYE) covering ophthalmology pipeline including Vitargus.
- Second milestone payment of $3.5M can now be paid incrementally (e.g., $100k) at any time, rather than a single lump sum.
- Amendment dated June 18, 2024; all other terms of the original March 25, 2024, license remain unchanged.

## SEC filing metadata
- accession: 0001213900-24-055288
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/0001213900-24-055288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/ea0208383-8ka1_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-055288
- JSON: https://secwatch.observer/filing/0001213900-24-055288.json
- Plain text: https://secwatch.observer/filing/0001213900-24-055288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.